Katherine B. Peters, MD, PhD, discusses how INDIGO (NCT04164901) findings may shift practice toward earlier treatment in IDH-mutant glioma, even after gross total resection, while highlighting ongoing questions around patient selection and long-term management.
The chief medical executive at Marcus Neuroscience Institute discussed the evolving role of AI, advanced imaging, and precision therapeutics in neurology presented at Baptist Health’s 2026 Brain & Spine Symposium. [WATCH TIME: 5 minutes]
The nurse practitioner at the University of Miami and the president of the IOMSN discussed advice for younger colleagues, misconceptions about neurology nursing, and more. [WATCH TIME: 10 minutes]
Learn how early Parkinson’s treatment choices—Azilect, Sinemet, and dose tweaks—shape daily life, side effects, and long-term confidence.
A patient recounts misdiagnosis, early Parkinson’s stiffness, freezing, anxiety, and smell loss—plus how symptoms reshape daily life and care.
The assistant professor of neurology and ophthalmology at NYU Grossman School of Medicine discussed findings presented at AAN 2026 on the use of optical coherence tomography in pediatric MS. [WATCH TIME: 8 minutes]
Karen Lynch, MD, MRCPI, senior global medical director at Sanofi, discusses how delayed diagnosis in CIDP can contribute to irreversible nerve damage, long-term disability, and reduced functional recovery. [WATCH TIME: 3 minutes]
Neurology News Network for the week ending May 16th, 2026. [WATCH TIME: 5 minutes]
The nurse practitioner at the University of Miami and the president of the IOMSN shared their thoughts on the unique demands of nursing in neurology, with a particular focus on their experience in multiple sclerosis nursing. [WATCH TIME: 6 minutes]
At AAN 2026, the professor of neurology at the University of South Florida discussed findings from the phase 3 NIMBLE trial assessing cemdisiran in generalized myasthenia gravis. [WATCH TIME: 5 minutes]
Experts discuss tailoring IVIG for CIDP—optimizing dose and intervals, monitoring relapse risk, and overcoming access and tolerability barriers.
The professor of neurology and director of the Division of Movement Disorders at the University of Alabama at Birmingham discussed 3-year data on AMT-130 and its potential as a disease-modifying gene therapy for Huntington disease. [WATCH TIME: 3 minutes]
Real-world CIDP data show IVIG slows disability progression and may ease pain, with insights on study limits and patient outcomes.
Richard Nowak, MD, MS, reviews 52-week efficacy data from the MINT trial, highlighting durable improvements in MG-ADL and QMG scores and what the evolving treatment-placebo separation means for long-term disease control.
Katherine B. Peters, MD, PhD, reviews the exploratory seizure analysis from the phase 3 INDIGO trial (NCT04164901), discussing the numerical reduction in seizure burden with vorasidenib, the limitations of patient-reported seizure data, and how clinicians should interpret these findings in practice.
The discussion explores the evolving management of myasthenia gravis (MG), focusing on treatment selection, sequencing, and strategies for switching therapies in clinical practice. The expert faculty highlight how the expanding range of targeted therapies, including FcRn inhibitors, complement inhibitors, and B-cell–depleting agents, has enabled more individualized, patient-centered care, balancing short-term symptom control with long-term disease management. The panelists emphasize a shift toward earlier, proactive optimization of therapy to improve long-term outcomes and reduce disease burden in patients with MG.
In honor of Stroke Awareness Month, the medical director for telestroke at Allegheny Health Network discussed how evolving imaging modalities may be reshaping stroke care. [WATCH TIME: 5 minutes]
Neurology News Network for the week ending May 9th, 2026. [WATCH TIME: 5 minutes]
Explore evidence-based CIDP therapy: IVIG dosing from the ICE trial, steroid tradeoffs, and how clinicians tailor treatment to comorbidities.
Richard Nowak, MD, MS, outlines the design of the phase 3 MINT trial, highlighting its patient population, forced steroid taper, and the rationale for extending evaluation to a 52-week randomized control period.
CIDP management tackles fatigue, pain, mood, and rehab—plus the hunt for early biomarkers and more effective therapies.
Katherine B. Peters, MD, PhD, reviews the phase 3 INDIGO trial (NCT04164901), highlighting its patient population, significant progression-free survival benefit, and the impact of vorasidenib on delaying disease progression and need for further intervention.
The pediatric neurologist at Johns Hopkins Medicine provided commentary on the FDA's decision, and also discussed the evolving SMA treatment landscape in general terms. [WATCH TIME: 11 minutes]
The director of the Center for Neurological Restoration at Cleveland Clinic commented on tavapadon’s D1-selective mechanism, clinical development, and potential role in treating Parkinson disease across stages. [WATCH TIME: 4 minutes]
The director of the Neuromuscular Division at the Medical University of South Carolina shared post hoc CHAMPION-MG trial findings at MDA 2026, suggesting ravulizumab may enable corticosteroid reduction while maintaining or improving clinical outcomes. [WATCH TIME: 4 minutes]
Following his symposium at the 2026 AAN Annual Meeting, science educator Bill Nye discussed his connection to Friedreich ataxia, emphasizing the importance of awareness, early diagnosis, and effective communication between clinicians and patients. [WATCH TIME: 4 minutes]
The associate chief quality officer at Nationwide Children’s Hospital discussed how AI-driven research initiatives within PERC are helping identify missed epilepsy diagnoses and improve care pathways in pediatric populations. [WATCH TIME: 3 minutes]
Neurology News Network for the week ending May 2nd, 2026. [WATCH TIME: 5 minutes]
In this episode, "Navigating CIDP Guidelines, Misdiagnosis, and Disease Variants," the panelists in neurology and neuromuscular medicine explore the practical utility of the 2021 EAN/PNS CIDP guidelines and the considerable complexity introduced by disease variants. The discussion opens with a question about monophasic CIDP, with one expert noting that 20–30% of patients can achieve drug-free remission after initial treatment, suggesting a subset of patients experience a self-limiting course that nonetheless meets the diagnostic threshold of progression or relapse beyond two months.
Richard Nowak, MD, MS, outlines the biologic rationale for CD19-targeted therapy in generalized myasthenia gravis, highlighting how inebilizumab differs from CD20-directed approaches and why broader B-cell depletion may offer clinical advantages.
